â– LECTURE OVERVIEW: Kawasaki Disease is an acute, self-limiting medium-vessel necrotizing vasculitis that primarily affects infants and toddlers.
â– SPECIFIC TOXIC CHANNELS:
1. Endothelial Inflammation: Characterized by segment-like inflammation of muscular medium arteries, particularly coronary arteries.
2. Clinical Diagnoses: Requires high fever lasting over 5 days, plus at least 4 of 5 CRASH symptoms:
- C - Conjunctivitis (bilateral, non-purulent, sparing the limbus).
- R - Rash (polymorphous, erythematous).
- A - Adenopathy (cervical, unilateral, node >1.5 cm).
- S - Strawberry tongue (erythematous, with cracked red lips).
- H - Hand/foot swelling initially, with desquamation of skin under nails in recovery.
â– PHARMACOKINETIC & PHARMACODYNAMIC ATTRIBUTES:
Absorption and steady-state kinetics display high variability based on plasma protein binding levels, tissue volume of distribution (Vd), and hepatic CYP450 microsomal enzymatic clearance indices.
â– GENOMIC VARIANT CHARACTERISTICS:
Molecular profiling indicates that specific genetic subtypes exhibit varying levels of enzyme activity and drug-clearance efficiency.
[HY-BOARD-1112]
🌟 Dynamic Clinical Key:
Carries a high risk of developing coronary artery aneurysms in up to 25% of untreated cases. Crucially, Kawasaki disease is the only clinical condition where Aspirin (which is otherwise contraindicated in children due to Reye's syndrome) is administered, alongside intravenous immunoglobulin (IVIG). Closely monitor serum plasma concentrations if drugs display a narrow therapeutic window to mitigate toxic peaks. Genetic screening profiles can help tailor precise therapeutic doses for optimal patient outcomes.